These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21983031)

  • 21. 14-3-3 Proteins--a focus on cancer and human disease.
    Wilker E; Yaffe MB
    J Mol Cell Cardiol; 2004 Sep; 37(3):633-42. PubMed ID: 15350836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The functional significance of 14-3-3 proteins in cancer: focus on lung cancer.
    Khorrami A; Sharif Bagheri M; Tavallaei M; Gharechahi J
    Horm Mol Biol Clin Investig; 2017 Aug; 32(3):. PubMed ID: 28779564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Foreword: neurodegenerative diseases: challenges and opportunities.
    Cuny GD
    Future Med Chem; 2012 Sep; 4(13):1647-9. PubMed ID: 22924500
    [No Abstract]   [Full Text] [Related]  

  • 24. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
    Liu R; Proud CG
    Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting GRK5 for Treating Chronic Degenerative Diseases.
    Marzano F; Rapacciuolo A; Ferrara N; Rengo G; Koch WJ; Cannavo A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug discovery targeting the mTOR pathway.
    Martelli AM; Buontempo F; McCubrey JA
    Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting 14-3-3zeta in cancer therapy.
    Yang X; Cao W; Zhang L; Zhang W; Zhang X; Lin H
    Cancer Gene Ther; 2012 Mar; 19(3):153-9. PubMed ID: 22193627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolomics as a tool for drug discovery and personalised medicine. A review.
    Mastrangelo A; Armitage EG; García A; Barbas C
    Curr Top Med Chem; 2014; 14(23):2627-36. PubMed ID: 25515755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of neurodegenerative diseases: emerging targets, treatments and technologies.
    Voss J; Ebert A; Wolfe M; Lindsley C; Cookson M; Deane R
    Future Med Chem; 2012 Sep; 4(13):1661-9. PubMed ID: 22924504
    [No Abstract]   [Full Text] [Related]  

  • 31. Multitarget network strategies to influence memory and forgetting: the Ras/MAPK pathway as a novel option.
    Gyurkó MD; Steták A; Sőti C; Csermely P
    Mini Rev Med Chem; 2015; 15(8):696-704. PubMed ID: 25694072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.
    Pair FS; Yacoubian TA
    Trends Pharmacol Sci; 2021 Apr; 42(4):226-238. PubMed ID: 33518287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression regulation through 14-3-3 interactions with histones and HDACs.
    Healy S; Khan DH; Davie JR
    Discov Med; 2011 Apr; 11(59):349-58. PubMed ID: 21524388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging role of the ubiquitin-proteasome system as drug targets.
    Kar G; Keskin O; Fraternali F; Gursoy A
    Curr Pharm Des; 2013; 19(18):3175-89. PubMed ID: 23151131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 14-3-3 proteins in neurodegeneration.
    Steinacker P; Aitken A; Otto M
    Semin Cell Dev Biol; 2011 Sep; 22(7):696-704. PubMed ID: 21920445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
    Gediya P; Parikh PK; Vyas VK; Ghate MD
    Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sumoylation: Implications for Neurodegenerative Diseases.
    Anderson DB; Zanella CA; Henley JM; Cimarosti H
    Adv Exp Med Biol; 2017; 963():261-281. PubMed ID: 28197918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.
    Myeku N; Duff KE
    Trends Mol Med; 2018 Jan; 24(1):18-29. PubMed ID: 29233753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small molecules modulation of 14-3-3 protein-protein interactions.
    Mori M; Vignaroli G; Botta M
    Drug Discov Today Technol; 2013 Dec; 10(4):e541-7. PubMed ID: 24451646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulators of 14-3-3 Protein-Protein Interactions.
    Stevers LM; Sijbesma E; Botta M; MacKintosh C; Obsil T; Landrieu I; Cau Y; Wilson AJ; Karawajczyk A; Eickhoff J; Davis J; Hann M; O'Mahony G; Doveston RG; Brunsveld L; Ottmann C
    J Med Chem; 2018 May; 61(9):3755-3778. PubMed ID: 28968506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.